You are here: Home » PTI Stories » National » News
Business Standard

Addressing points raised by USFDA: Vista Pharma

Press Trust of India  |  New Delhi 

today said it is addressing all the issues raised by the US health regulator in a warning letter to the company for its Nalgonda facility in

The Hyderabad-based company has been issued a warning letter by the United States Food and Drug Administration (USFDA) over significant violations of good manufacturing norms at its Nalgonda plant.

USFDA has issued a warning letter in response to the company's detailed reply submitted on October 2016, said in a filing to

"We wish to inform all stakeholders that all the points mentioned in the letter are being addressed and we shall respond with complete details of our remedial actions to USFDA before the stipulated date," it added.

On account of this, there is no disruption of our operations and "no loss is envisaged", the company said.

of today closed at Rs 31.15 per scrip on BSE, down 4.89 per cent from its previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Thu, July 13 2017. 17:22 IST